Herd immunity: recent uses in vaccine assessment

References

• Berger A. How does herd immunity work? BMJ319, 1466–1467 (1999).
   PubMed Web of Science ®Google Scholar
• Fox JP, Helveback L, Scott W, Gatewood L, Ackerman E. Herd immunity: basic concept and relevance to public health immunization practices. Am. J. Epidemiol.94(3), 179–189 (1971).
   PubMed Web of Science ®Google Scholar
• Fine PEM, Mulholland K. Community immunity. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA (Eds). Saunders, Elsevier, PA, USA 1573–1592 (2008).
   Google Scholar
• John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur. J. Epidemiol.16(7), 601–606 (2000).
   PubMed Web of Science ®Google Scholar
• Forte WN. Imunologia básica e aplicada. ARTMED® Editora S.A., Porto Alegre, Brasil (2004).
   Google Scholar
• Ada G. The immunology of vaccination. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Ed.). Saunders Elsevier, PA, USA 31–45 (2004).
   Google Scholar
• Anderson RM. The concept of herd immunity and the design of community-based immunization programmes. Vaccine10(13), 928–935 (1992).
   PubMed Web of Science ®Google Scholar
• Fine PEM. Herd immunity: history, theory and practice. Epidemiol. Rev.15, 265–302 (1993).
   PubMed Web of Science ®Google Scholar
• Fine PEM. Community immunity. In: Vaccines (4th Edition). Plotkin SA, Orenstein WA (Eds). Saunders Elsevier, PA, USA 1443–1461 (2004).
   Google Scholar
• Mühlemann K, Weiss NS. Can herd immunity influence the assessment of vaccine efficacy in nonrandomized studies? Am. J. Public Health87(1), 113–114 (1997).
   PubMed Web of Science ®Google Scholar
• Paul Y. Herd immunity and herd protection. Vaccine22(3–4), 301–302 (2004).
   PubMed Web of Science ®Google Scholar
• Tennenbaum S. Simple criteria for finding (nearly) optimal vaccination strategies. J. Theor. Biol.250(4), 673–683 (2008).
   PubMed Web of Science ®Google Scholar
• Last JM (Ed.). A Dictionary of Epidemiology. (4th Edition). Oxford University Press, Oxford, UK (2001).
   Google Scholar
• Maia JOC. Some mathematical developments of the epidemic theory formulated by Reed and Frost. Hum. Biol.24, 167–200 (1952).
   PubMedGoogle Scholar
• Popper KR. Unended Quest: an Intellectual Autobiography. Routledge, UK (2002).
   Google Scholar
• Ferrari MJ, Bansal S, Meyers LA, Bjørnstad ON. Network frailty and the geometry of herd immunity. Proc. Biol. Sci.273(1602), 2743–2748 (2006).
   PubMed Web of Science ®Google Scholar
• Bauch CT. Imitation dynamics predict vaccinating behaviour. Proc. Biol. Sci.272(1573), 1669–1675 (2005).
   PubMed Web of Science ®Google Scholar
• Cojocaru MG, Bauch CT, Johnston MD. Dynamics of vaccination strategies via projected dynamical systems. Bull. Math. Biol.69(5), 1453–1476 (2007).
   PubMed Web of Science ®Google Scholar
• Boëlle PY. Theoretical epidemiology and vaccine. Rev. Med. Interne28(3), 161–165 (2007).
   PubMed Web of Science ®Google Scholar
• Kim SY, Goldie SJ. Cost–effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics26(3), 191–215 (2008).
   PubMed Web of Science ®Google Scholar
• Pradas-Velasco R, Antoñanzas-Villar F, Martínez-Zárate MP. Dynamic modelling of infectious diseases: an application to the economic evaluation of influenza vaccination. Pharmacoeconomics26(1), 45–56 (2008).
   PubMed Web of Science ®Google Scholar
• Szucs TD. Health economic research on vaccinations and immunisation practices – an introductory primer. Vaccine23(17–18), 2095–2103 (2005).
   PubMed Web of Science ®Google Scholar
• Dawson A. Vaccination and the prevention problem. Bioethics18(6), 515–530 (2004).
   PubMed Web of Science ®Google Scholar
• May T, Silverman RD. Free-riding, fairness and the rights of minority groups in exemption from mandatory childhood vaccination. Hum. Vaccin.1(1), 12–15 (2005).
   PubMed Web of Science ®Google Scholar
• Calandrillo SP. Vanishing vaccinations: why are so many Americans opting out of vaccinating their children? Univ. Mich. J. Law Reform37(2), 353–440 (2004).
   PubMedGoogle Scholar
• Dawson A. What are the moral obligations of the traveller in relation to vaccination? Travel. Med. Infect. Dis.5(2), 90–96 (2007).
   PubMedGoogle Scholar
• Verweij MF, van den Hoven MA. Influenza vaccination in Dutch nursing homes: is tacit consent morally justified? Med. Health Care Philos.8(1), 89–95 (2005).
   PubMedGoogle Scholar
• Kahn J. What vaccination programs mean for research. Am. J. Bioeth.7(3), 3–4 (2007).
   PubMed Web of Science ®Google Scholar
• Congeni BL. Vaccine shortages eliminate possibility for excess capacity in stockpiles. Pediatr. Ann.33(9), 577–583 (2004).
   PubMed Web of Science ®Google Scholar
• McIntosh ED. Paediatric infections: prevention of transmission and disease – implications for adults. Vaccine23(17–18), 2087–2089 (2005).
   PubMed Web of Science ®Google Scholar
• Elliott C, Farmer K. Immunization status of children under 7 years in the Vikas Nagar area, North India. Child Care Health Dev.32(4), 415–421 (2006).
   PubMed Web of Science ®Google Scholar
• Menzies R, McIntyre P. Vaccine preventable diseases and vaccination policy for indigenous populations. Epidemiol. Rev.28, 71–80 (2006).
   PubMed Web of Science ®Google Scholar
• Heymann DL, Aylward RB. Mass vaccination: when and why. Curr. Top. Microbiol. Immunol.304, 1–16 (2006).
   PubMed Web of Science ®Google Scholar
• Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J. Infect. Dis.191(Suppl. 1), S97–S106 (2005).
   PubMed Web of Science ®Google Scholar
• Schellekens J, von König CH, Gardner P. Pertussis sources of infection and routes of transmission in the vaccination era. Pediatr. Infect. Dis J.24(5 Suppl.), S19–S24 (2005).
   PubMedGoogle Scholar
• Tan T, Halperin S, Cherry JD et al. Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr. Infect. Dis. J.24(5 Suppl.), S83–S86 (2005).
   PubMedGoogle Scholar
• Esen B, Coplu N, Kurtoglu D, Gozalan A, Akin L. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. J. Clin. Lab. Anal.21(3), 154–161 (2007).
   PubMed Web of Science ®Google Scholar
• Lee GM, Murphy TV, Lett S et al. Cost effectiveness of pertussis vaccination in adults. Am. J. Prev. Med.32(3), 186–193 (2007).
   PubMed Web of Science ®Google Scholar
• Casey JR, Pichichero ME. Acellular pertussis vaccine safety and efficacy in children, adolescents and adults. Drugs65(10), 1367–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Acellular pertussis vaccines for adolescents. Pediatr. Infect. Dis. J.24(6 Suppl.), S117–S126 (2005).
   Web of Science ®Google Scholar
• Pósfay-Barbe KM. Whooping cough: a diagnosis one shouldn’t forget. Rev. Med. Suisse2(54), 503–506, 509–511 (2006).
   PubMedGoogle Scholar
• Byrne S, Slack AT. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999–2003. BMC Infect. Dis.6, 53 (2006).
   PubMed Web of Science ®Google Scholar
• Gomes MG, White LJ, Medley GF. The reinfection threshold. J. Theor. Biol.235(2), 151–152 (2005).
   PubMed Web of Science ®Google Scholar
• Águas R, Gonçalves G, Gomes MGM. Pertussis: increasing disease as a consequence of reducing transmission. Lancet Infect. Dis.6, 112–117 (2006).
   PubMed Web of Science ®Google Scholar
• Robbins JB, Schneerson R, Keith JM, Shiloach J, Miller M, Trollors B. The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP. Vaccine25(15), 2811–2816 (2007).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, El-Hadi W, Payne K, O’Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr. Infect. Dis. J.24(5 Suppl.), S75–S82 (2005).
   PubMedGoogle Scholar
• Ali M, Emch M, Yunus M, Sack D et al. Vaccine protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr. Infect. Dis. J.27(1), 33–37 (2008).
   PubMed Web of Science ®Google Scholar
• Longini IM Jr, Nizam A, Ali M, Yunus M, Shenvi N, Clemens JD. Controlling endemic cholera with oral vaccines. PLoS Med.4(11), e336 (2007).
   PubMed Web of Science ®Google Scholar
• Sánchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr. Opin. Immunol.17(4), 388–398 (2005).
   PubMed Web of Science ®Google Scholar
• Makwana N, Riordan FA. Bacterial meningitis: the impact of vaccination. CNS Drugs21(5), 355–366 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang Q, Finn A. Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J. Clin. Pathol.57(10), 1015–1021 (2004).
   PubMed Web of Science ®Google Scholar
• Miranzi Sde S, Moraes SA, Freitas IC. Trends in Haemophilus influenzae type b meningitis in Brazil in children under five years of age from 1983 through 2002. Rev. Soc. Bras. Med. Trop.39(5), 473–477 (2006).
   PubMed Web of Science ®Google Scholar
• Ladhani S, Slack MP, Heys M, White J, Ramsay ME. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch. Dis. Child.93, 665–669 (2007).
   PubMed Web of Science ®Google Scholar
• Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost–utility of universal hepatitis A vaccination in Canada. Vaccine25(51), 8536–8548 (2007).
   PubMed Web of Science ®Google Scholar
• André FE. Universal mass vaccination against hepatitis A. Curr. Top. Microbiol. Immunol.304, 95–114 (2006).
   PubMed Web of Science ®Google Scholar
• Lopez E, Debbag R, Coudeville L, Baron-Papillon F, Armoni J. The cost–effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health – economic analysis. J. Gastroenterol.42(2), 152–160 (2007).
   PubMed Web of Science ®Google Scholar
• Genton B, D’Acremont V, Furrer HJ, Hatz C, Loutan L. Hepatitis A vaccines and the elderly. Travel. Med. Infect. Dis.4(6), 303–312 (2006).
   PubMedGoogle Scholar
• Hollinger FB, Bell B, Levy-Bruhl D, Shouval D, Wiersma S, Van Damme P. Hepatitis A and B vaccination and public health. J. Viral. Hepat.14(Suppl. 1), 1–5 (2007).
   PubMed Web of Science ®Google Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA294(2), 202–210 (2005).
   PubMed Web of Science ®Google Scholar
• Domínguez A, Oviedo M, Carmona G et al. Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine26(14), 1737–1741 (2008).
   PubMed Web of Science ®Google Scholar
• Wasley A, Fiore A, Bell BP. Hepatitis A in the era of vaccination. Epidemiol. Rev.28, 101–111 (2006).
   PubMed Web of Science ®Google Scholar
• Van Effelterre TP, Zink TK, Hoet BJ, Hausdorff WP, Rosenthal P. A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization. Clin. Infect. Dis.43(2), 158–164 (2006).
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Billah K, Rein DB, Hicks KA, Wirth KE, Bell BP. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity. Pediatrics119(1), e22–e29 (2007).
   PubMed Web of Science ®Google Scholar
• Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylatic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ177(5), 469–479 (2007).
   PubMed Web of Science ®Google Scholar
• Cutts FT, Fransceschi S, Goldie S et al. Human papillomavirus and HPV vaccines: a review. Bull. WHO85(9), 719–716 (2007).
   PubMed Web of Science ®Google Scholar
• Lippman A, Boscoe M, Scurfield C. Do you approve of spending $300 million on HPV vaccination? No. Can. Fam. Physician54, 175–177 (2008).
   PubMed Web of Science ®Google Scholar
• Regan DG, Philp DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex. Health4(3), 147–163 (2007).
   PubMed Web of Science ®Google Scholar
• Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol. Rev.28, 88–100 (2006).
   PubMed Web of Science ®Google Scholar
• Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost–effectiveness of human papillomavirus vaccination in the United States. Emerg. Infect. Dis.14(2), 244–251 (2008).
   PubMed Web of Science ®Google Scholar
• Kulasingam S, Connelly L, Conway E et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex. Health4(3), 165–175 (2007).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Gaglani MJ, Kozinetz CA et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine23(13), 1540–1548 (2005).
   PubMed Web of Science ®Google Scholar
• Piedra PA, Gaglani MJ, Kozinetz CA et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003–2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics120(3), e553–e564 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz B, Hinman A, Abramson J et al. Universal influenza vaccination in the United States: are we ready? Report of a meeting. J. Infect. Dis.194(Suppl. 2), S147–S154 (2006).
   PubMedGoogle Scholar
• Chantler T, Pace D, Wright A et al.Uptake and acceptability of influenza vaccination in day nursery children. Community Pract.80(12), 32–36 (2007).
   PubMedGoogle Scholar
• Wu JT, Riley S, Leung GM. Spatial considerations for the allocation of pre-pandemic influenza vaccination in the United States. Proc. Biol. Sci.274(1627), 2811–2817 (2007).
   PubMed Web of Science ®Google Scholar
• Saffar MJ, Amiri-Alreza M, Baba-Mahmoodi F, Saffar H. Measles epidemiology in Mazandaran province, Iran, 2000–2002. Trop. Doct.37(1), 30–32 (2007).
   PubMed Web of Science ®Google Scholar
• Rentsen T, Enkhtuya B, Nymadawa P et al. Measles outbreak after a post-honeymoon period in Mongolia, 2001. Jpn. J. Infect. Dis.60(4), 198–199 (2007).
   PubMed Web of Science ®Google Scholar
• Hyde TB, Dayan GH, Langidrik JR et al. Measles outbreak in the Republic of the Marshall Islands, 2003. Int. J. Epidemiol.35(2), 299–306 (2006).
   PubMed Web of Science ®Google Scholar
• Ong G, Hoon HB, Ong A, Chua LT, Kai CS, Tai GK. A 24-year review on the epidemiology and control of measles in Singapore, 1981–2004. Southeast Asian J. Trop. Med. Public Health37(1), 96–101 (2006).
   PubMedGoogle Scholar
• Friederichs V, Cameron JC, Robertson C. Impact of adverse publicity on MMR vaccine uptake: a population based analysis of vaccine uptake records for one million children, born 1987–2004. Arch. Dis. Child.91(6), 465–468 (2006).
   PubMed Web of Science ®Google Scholar
• Wallinga J, Heijne JC, Kretzschmar M. A measles epidemic threshold in a highly vaccinated population. PLoS Med.2(11), e316 (2005).
   PubMed Web of Science ®Google Scholar
• Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine24(22), 4692–4700 (2006).
   PubMed Web of Science ®Google Scholar
• Maiden MC, Ibarz-Pavón AB, Urwin R et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis.197(5), 737–743 (2008).
   PubMed Web of Science ®Google Scholar
• Borrow R, Miller E. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned. Expert Rev. Vaccines5(6), 851–857 (2006).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Gay NJ, Edmunds WJ. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol.162(1), 89–100 (2005).
   PubMed Web of Science ®Google Scholar
• Ortega-Sanchez IR, Meltzer MI, Shepard C et al. Active Bacterial Core Surveillance Team. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Clin. Infect. Dis.46(1), 1–13 (2008).
   PubMed Web of Science ®Google Scholar
• Caro JJ, Möller J, Getsios D et al. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation. BMC Public Health7(147), 130 (2007).
   PubMed Web of Science ®Google Scholar
• De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in Canada: a cost–effectiveness analysis. Vaccine25(29), 5433–5440 (2007).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Edmunds WJ. Reassessing the cost–effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model. Med. Decis. Making26(1), 38–47 (2006).
   PubMed Web of Science ®Google Scholar
• Hviid A, Rubin S, Mühlemann K. Mumps. Lancet371(9616), 932–944 (2008).
   PubMed Web of Science ®Google Scholar
• Muhsen Kh, Aboudy Y, Mendelson E, Green MS, Cohen D. Prevalence of mumps antibodies in the Israeli population in relation to mumps vaccination policy and incidence of disease. Epidemiol. Infect.136(5), 688–693 (2008).
   PubMed Web of Science ®Google Scholar
• Donaghy M, Cameron JC, Friederichs V. Increasing incidence of mumps in Scotland: options for reducing transmission. J. Clin. Virol.35(2), 121–129 (2006).
   PubMed Web of Science ®Google Scholar
• Gijalva CG, Griffin MR. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA. Expert Rev. Vaccines7(1), 83–95 (2008).
   PubMed Web of Science ®Google Scholar
• Pebody RG, Leino T, Nohynek H, Hellenbrand W, Salmaso S, Ruutu P. Pneumococcal vaccination policy in Europe. Euro. Surveill.10(9), 174–178 (2005).
   PubMedGoogle Scholar
• Haber M, Barskey A, Baughman W et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine25(29), 5390–5398 (2007).
   PubMed Web of Science ®Google Scholar
• Clarke SC, Jefferies JM, Smith AJ, McMenamin J, Mitchell TJ, Edwards GF. Potential impact of conjugate vaccine on the incidence of invasive pneumococcal disease among children in Scotland. J. Clin. Microbiol.44(4), 1224–1228 (2006).
   PubMed Web of Science ®Google Scholar
• Claes C, Reinert RR, von der Schulenburg JM. Cost–effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur. J. Health. Econ. DOI: 10.1007/s10198-008-0098-1 (2008) (Epub ahead of print).
   Google Scholar
• Isaacman DJ, Strutton DR, Kalpas EA et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin. Ther.30(2), 341–357 (2008).
   PubMed Web of Science ®Google Scholar
• Lloyd A, Patel N, Scott DA, Runge C, Claes C, Rose M. Cost–effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur. J. Health Econ.9(1), 7–15 (2008).
   PubMed Web of Science ®Google Scholar
• Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. Enhanced decision support for policy makers using a web interface to health-economic models – illustrated with a cost–effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in The Netherlands. Vaccine25(18), 3669–3678 (2007).
   PubMed Web of Science ®Google Scholar
• Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination – a review (2002–2006). Vaccine25(8), 1355–1367 (2007).
   PubMed Web of Science ®Google Scholar
• Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost–effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J.25(6), 494–501 (2006).
   PubMed Web of Science ®Google Scholar
• McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A. Pneumococcal pneumonia in the UK – how herd immunity affects the cost–effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine23(14), 1739–1745 (2005).
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost–effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine22(31–32), 4203–4214 (2004).
   PubMed Web of Science ®Google Scholar
• Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int. J. Antimicrob. Agents32, 199–206 (2008).
   PubMed Web of Science ®Google Scholar
• O’Brien KL, Millar EV, Zell ER et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J. Infect. Dis.196(8), 1211–1220 (2007).
   PubMed Web of Science ®Google Scholar
• Vila-Córcoles A. Advances in pneumococcal vaccines: what are the advantages for the elderly? Drugs Aging24(10), 791–800 (2007).
   PubMed Web of Science ®Google Scholar
• Benninger MS. Acute bacterial rhinosinusitis and otitis media: changes in pathogenicity following widespread use of pneumococcal conjugate vaccine. Otolaryngol. Head Neck Surg.138(3), 274–278 (2008).
   PubMed Web of Science ®Google Scholar
• Lipsitch M, O’Neill K, Cordy D et al. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J. Infect. Dis.196(8), 1221–1227 (2007).
   PubMed Web of Science ®Google Scholar
• Dagan R. The potential effect of widespread use of pneumococcal conjugate vaccines on the practice of pediatric otolaryngology: the case of acute otitis media. Curr. Opin. Otolaryngol. Head Neck Surg.12(6), 488–494 (2004).
   PubMedGoogle Scholar
• Adamkiewicz TV, Silk BJ, Howgate J et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics121(3), 562–569 (2008).
   PubMed Web of Science ®Google Scholar
• Tasslimi A, Wenger P, Pentakota SR, Brimacombe M, Burday M, Sinha A. Invasive pneumococcal disease in an underimmunized, high HIV prevalence population. J. Infect.56(2), 99–102 (2008).
   PubMed Web of Science ®Google Scholar
• Fletcher MA, Laufer DS, McIntosh ED, Cimino C, Malinoski FJ. Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient? Int. J. Clin. Pract.60(4), 450–456 (2006).
   PubMed Web of Science ®Google Scholar
• Klugman KP, Madhi SA, Feldman C. HIV and pneumococcal disease. Curr. Opin. Infect. Dis.20(1), 11–15 (2007).
   PubMed Web of Science ®Google Scholar
• Mackenzie G, Carapetis J, Leach AJ, Hare K, Morris P. Indirect effects of childhood pneumococcal vaccination on pneumococcal carriage among adults and older children in Australian Aboriginal communities. Vaccine25(13), 2428–2433 (2007).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Auranen K, Nohynek H, Dagan R, Mäkelä H. Nasopharyngeal colonization: a target for pneumococcal vaccination. Expert Rev. Vaccines5(5), 651–667 (2006).
   PubMed Web of Science ®Google Scholar
• Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine24(4), 468–475 (2006).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease – United States, 1998–2003. MMWR Morb. Mortal. Wkly Rep.54(36), 893–897 (2005).
   PubMedGoogle Scholar
• Shafinoori S, Ginocchio CC, Greenberg AJ, Yeoman E, Cheddie M, Rubin LG. Impact of pneumococcal conjugate vaccine and the severity of winter influenza-like illnesses on invasive pneumococcal infections in children and adults. Pediatr. Infect. Dis. J.24(1), 10–16 (2005).
   PubMed Web of Science ®Google Scholar
• McClure CA, Ford MW, Wilson JB, Aramini JJ. Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: recommendations and expected benefits. Can. J. Infect. Dis. Med. Microbiol.17(1), 19–26 (2006).
   PubMedGoogle Scholar
• Black S, Shinefield H, Baxter R et al. Impact of the use of heptavalent pneumococcal conjugate vaccine on disease epidemiology in children and adults. Vaccine24(Suppl. 2), S79–S80 (2006).
   Google Scholar
• Poehling KA, Talbot TR, Griffin MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA295(14), 1668–1674 (2006).
   PubMed Web of Science ®Google Scholar
• Isaacman DJ, Fletcher MA, Fritzell B, Ciuryla V, Schranz J. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar). Vaccine25(13), 2420–2427 (2007).
   PubMed Web of Science ®Google Scholar
• Watson M, Roche P, Bayley K et al. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program. Commun. Dis. Intell.28(4), 455–464 (2004).
   Google Scholar
• Ho CF, Lin TY. Pneumococcal vaccines. Chang. Gung. Med. J.28(11), 765–772 (2005).
   PubMedGoogle Scholar
• Temime L, Dab W. Pneumococcal vaccination: expected benefits in adults. Rev. Med. Interne28(1), 9–15 (2007).
   PubMed Web of Science ®Google Scholar
• Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA297(16), 1784–1792 (2007).
   PubMed Web of Science ®Google Scholar
• Dias R, Caniça M. Invasive pneumococcal disease in Portugal prior and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol. Med. Microbiol.51, 25–42 (2007).
   Google Scholar
• Iwai M, Takizawa T, Nakayama T et al. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scand. J. Infect. Dis.40(3), 247–253 (2008).
   PubMed Web of Science ®Google Scholar
• Gidding HF, Backhouse JL, Gilbert GL, Burgess MA. National serosurvey of poliovirus immunity in Australia, 1996–1999. Aust. NZ J. Public Health29(1), 48–52 (2005).
   PubMed Web of Science ®Google Scholar
• Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin. Microbiol. Infect.11(1), 68–71 (2005).
   PubMed Web of Science ®Google Scholar
• Wang IJ, Huang LM, Chen HH, Hwang KC, Chen CJ. Seroprevalence of rubella infection after national immunization program in Taiwan: vaccination status and immigration impact. J. Med. Virol.79(1), 97–103 (2007).
   PubMed Web of Science ®Google Scholar
• Huerta M, Davidovitch N, Ankol OE et al. Declining seroprevalence of rubella antibodies among young Israeli adults: a 12-year comparison. Prev. Med.39(6), 1223–1226 (2004).
   PubMed Web of Science ®Google Scholar
• Dashraath P, Ong ES, Lee VJ. Seroepidemiology of varicella and the reliability of a self-reported history of varicella infection in Singapore military recruits. Ann. Acad. Med. Singapore36(8), 636–641 (2007).
   PubMed Web of Science ®Google Scholar
• Marcitelli R, Bricks LF. Varicella zoster in children attending day care centers. Clinics61(2), 147–152 (2006).
   PubMedGoogle Scholar
• Marin M, Watson TL, Chaves SS et al. Varicella among adults: data from an active surveillance project, 1995–2005. J. Infect. Dis.197(Suppl. 2), S94–S100 (2008).
   PubMed Web of Science ®Google Scholar
• Lopez AS, Guris D, Zimmerman L et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? Pediatrics117(6), e1070–e1077 (2006).
   PubMed Web of Science ®Google Scholar
• Quian J, Rüttimann R, Romero C et al. Impact of universal varicella vaccination of one year-olds in Uruguay: 1997–2005. Arch. Dis. Child.93, 845–850 (2008).
   PubMed Web of Science ®Google Scholar
• Heininger U, Seward JF. Varicella. Lancet368(9544), 1365–1376 (2006).
   PubMed Web of Science ®Google Scholar
• Nardone A, de Ory F, Carton M et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine25(45), 7866–7872 (2007).
   PubMed Web of Science ®Google Scholar
• Gonçalves G. Incerteza e Riscos em Epidemiologia e Saúde Pública. In: Encontro de Saberes. Três Gerações de Bolseiros da Gulbenkian. Tostões A, Arantes e Oliveira ER, Paixão JMP, Magalhães P (Eds). Fundação Calouste Gulbenkian, Lisbon, Portugal 455–471 (2006).
   Google Scholar
• Last JM. Epidemiology and public health. In: Teaching Epidemiology. A Guide for Teachers in Epidemiology, Public Health and Clinical Medicine (2nd Edition). Olsen J, Saracci R, Trichopoulos D (Eds). Oxford University Press, Oxford, UK, 21–32 (2001).
   Google Scholar